TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Surgical Conversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Long-term patient-reported quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Recurrence of nonsyndromic cleft lip with or without cleft palate
Endpoint domain: Mortality/survival
Primary endpoint: Interstitial cystitis symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: MARR (mobilization adjusted response rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EFS (event free survival)
Endpoint domain: Mortality/survival
Primary endpoint: Completion of the intended surgical procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Proportion of subjects that require electrocautery or any other intervention post catheter removal
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Improvement in CF related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Rate of device related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Extent of complete exclusion of the LAA with minimal residual cavity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weekly mean of 24-hour average pain score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Mean value of the perfusion index (PI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fuld Object Memory Evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Symbol Digit Modalities Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mini-Mental State Examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Surgeon perceptions to telemedicine
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient perceptions to telemedicine
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Asthma Quality of Life Questionnaire scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in stool microbiota profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median Event Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Time spent with MAP < 85 mmHg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum urethral flow value (Q-max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of ventricular and atrial arrhythmias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to Successful intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Metabolic adaptations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Neural adaptations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Accuracy of Breathe Well
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Total Score of Standardized Mini-Mental State Examination (sMMSE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Feasibility of retention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Feasibility for participant adherence
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Acceptability of study procedures
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Serum urate level decrease to < 6.0 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence Rate of Factor VIII Inhibitors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of regulatory T cells in lesional skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of subjects anesthetized
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With a Hemoglobin Value of 11-12 g/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Participants With a Hemoglobin Value of 11-13 g/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Average Duration in Months Mircera Was Administered at Current Dose
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Sharing genetic test results with at-risk relatives
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: At-risk relatives pursuing genetic testing
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of prostate cancer foci detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Severity of UFS symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Acceptability of the P-COCC intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence, severity, dose-relationship of adverse effects
Endpoint domain: Adverse events/effects
Primary endpoint: Change in plasma HbA1c levels at Week 27 compared to Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cognitive test grade
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Liver fibrosis evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Incidence of study agent interruption
Endpoint domain: Adverse events/effects
Primary endpoint: Adult height gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PBMC Gene Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: General tolerability and safety
Endpoint domain: Adverse events/effects
Primary endpoint: Left atrial fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of participants responded to treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Employment or enrollment in vocational classes
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Device Securement Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Ankle Functional Stability via the Single-leg Hop for Distance Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ankle Functional Stability via the Single-leg Hops for Time Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endurance of Ankle Dorsiflexor Muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Endurance of Ankle Plantar Flexor Muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Harris Hip Score Evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Radiologic Failure of Device
Endpoint domain: Adverse events/effects
Primary endpoint: bioavailability of lersivirine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hemodynamic stability during dialysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of Maximum Observed Plasma Concentration (Tmax) of Belatacept
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half-Life of Elimination (T-Half) of Belatacept
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of THC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-t) of THC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-∞) of THC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of 11-hydroxy-THC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-t) of 11-hydroxy-THC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-∞) of 11-hydroxy-THC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve from time 0 to last quantifiable concentration (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Total Muscle Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: PFS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: inpatient bed days
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Glomerular Filtration Rate Estimated from Serum Creatinine (eGFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Glomerular Filtration Rate by Plasma Iohexol Clearance (iGFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Protein Excretion Assessed from Three First-Morning Urine Voids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Post operative complication rate
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum dose tolerability of Selumetinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Pain Beliefs Questionnaire Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Baseline Revised Neurophysiology of Pain Questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Baseline Physical Activity Subscale of the Fear Avoidance Belief Questionnaire Scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Patient Reported Outcome Scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Patient and Observer Scar Assessment Scale Surveys
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Survival by Day+100 Post Stem Cell Transplant or Chemotherapy
Endpoint domain: Mortality/survival
Primary endpoint: neurophysiologic findings of cortical plasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: motor function changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with non-serious and serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in Microparticle tissue factor (MP-TF) activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Care Transition Measure-3 score (CTM-3)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Vitamin D blood level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Correlation of neural signatures with disease severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Accuracy of implant alignment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Proportion of Patients with radiographic fusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in percentage of steroid sulphatase (STS) inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive Screening Results
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: S100B Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Predictive ability of LUS for respiratory failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Post-occlusive hyperemia response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Amount of Daily Rescue Medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Generation of a minimum of 5 x 10^6 natural killer/kg cells in at least 60% of patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of adverse events graded using National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0
Endpoint domain: Adverse events/effects
Primary endpoint: Practice of oral hygiene
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement between measurement of ureteral length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urological Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Favourable outcome
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence of regimen limiting toxicities (RLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients Alive at 8 Months
Endpoint domain: Mortality/survival
Primary endpoint: Change from Baseline Anxiety State
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from Baseline Mood States
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from Baseline Exercise Experience
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Signing rate of support workers and individuals with intellectual disabilities
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Sign imitation rate support workers and individuals with intellectual disabilities
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Treatment-related adverse events during 30 week period of immunotherapy
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of subjects with plasma viral load <50 copies/ml after end of step 4 after ART therapy interruption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: HE grade improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood Oxygen-Level Dependent (BOLD) signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Serum Biomarker Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability to patients of randomisation procedures
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Physical Performance Test (PPT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain Ketone Utilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Antihyperalgesic effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Rankin Scale (mRS) <=3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of diabetic foot infection (DFI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-Time Curve From time Zero Extrapolated to Infinity (AUC [0-inf])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration (AUC [0-last])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive area under the curve for plasma glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of persistent post-operative pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Chronic Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of pain with typical features of neuropathic pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body composition data
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emotional processing (z score)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Functional measures of social interaction
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change in Quality of Life (EPP-QoL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Quality of Life (DLQI)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Changes in functions of immunocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of expected and unexpected adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of adherence to SAT-008
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Reduction of LDL Cholesterol Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of Osteoporosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Predict delivery within 7 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: SF12 Health survey
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Transplant Symptom Frequency and Symptom Distress Scale
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in Number of Incontinence Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemispheric stroke scale (HSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Percent reduction in incontinence episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: COVID-19 infection
Endpoint domain: Mortality/survival
Primary endpoint: energy intake of the meal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time of thick smear positivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: parasitemia as measured by 18S Pf NASBA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: kinetics of parasitemia as measured by 18S Pf NASBA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: occurrence or height of fever
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Alcohol Impaired Driving Behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-Reported Karnofsky Performance Score (KPS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Accuracy of lung mechanics measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes in scores on self-report measure of everyday cognition (subjective)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes in scores on self-report measure of everyday cognition (objective)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Concentration of Fluoride in Biofilm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of Fluoride in Toenails
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transfusion of blood components
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Count of Participants With Primary Graft Dysfunction (PGD), Grade 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Count of Participants Surviving
Endpoint domain: Mortality/survival
Primary endpoint: Microperimetry retinal sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intramyocellular lipid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: oxidative capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Side Effects
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of Participants With Anterior Chamber Cell (ACC) Grade 0
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Symptom Assessment-45 Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change of Sexual Compulsivity Scale (SCS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change of Safer Sex Self-Efficacy Questionnaire (SSSE)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Heart rate variability parameters (HRV, DET, RR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EMG of suprahyoid muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contrast changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glycosylated Haemoglobin (HbA1c) Value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Self Measured Blood Glucose (SMBG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: level of BCR-ABL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Combined Score (CS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes